PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35169250-5	2022	We aimed to investigate the therapeutic efficacy of tofacitinib and metformin on IL-17 and TGF-beta cytokines, skin fibrosis and inflammation in mouse model of systemic sclerosis (SSc).	Metformin	68-77	interleukin 17A	Mus musculus	81-86	
31164166-10	2019	Moreover, metformin reduced the interleukin (IL)-6, tumor necrosis factor-alpha, IL-17 mRNA, and protein levels in the salivary glands.	Metformin	10-19	interleukin 17A	Mus musculus	81-86	
33947424-9	2021	These results suggest that metformin treatment has anti-inflammatory effects on lymphocytes via the inhibition of IL-17 and cytokines related to Th17 differentiation, such as IL-1beta, IL-6, and TNF-alpha.	Metformin	27-36	interleukin 17A	Mus musculus	114-119	
31105845-8	2019	Treatment of NOD mice with metformin significantly mitigated autoimmune insulitis and substantially decreased the number of pro-inflammatory IFN-gamma+ as well as IL17+ CD4 T cells in the spleens of NOD mice.	Metformin	27-36	interleukin 17A	Mus musculus	163-167	
25370454-7	2015	These observations were further supported by the fact that metformin treatment inhibited CD3/CD28-induced IFN-gamma and IL-17A expression along with the transcription factors that drive their expression (T-bet [Th1] and ROR-gammat [Th17], respectively).	Metformin	59-68	interleukin 17A	Mus musculus	120-126